Samjin Pharmaceutical is partnering with AriBio LAB, a next-generation vaccine corporations, to jointly develop and commercialize shingles and hepatitis B vaccines.
Samjin Pharmaceutical said on Apr. 1 that it signed a memorandum of understanding (MOU) with AriBio LAB on Mar. 28 for a "strategic alliance for joint vaccine development and commercialization."
Under this agreement, the two companies will combine research and development (R&D) capabilities and technologies to pursue vaccine development cooperation. At the future product commercialization stage, the company plans to leverage Samjin Pharmaceutical's domestic medical institution sales network and prescription drug marketing capabilities to expand the market.
First, they will seek ways to cooperate on domestic sales and commercialization of the shingles preventive vaccine and the hepatitis B vaccine (therapeutic and preventive) that AriBio LAB is developing.
They will also pursue joint research and development using AriBio LAB's proprietary immune-boosting platforms, "L-pampo" and "Lipo-pam," to enhance the efficacy and competitiveness of various vaccine pipelines.
AriBio LAB has immune-boosting technology based on the mechanism of toll-like receptors (TLR). TLR-based immune-boosting technology is a next-generation vaccine platform that stimulates innate immune receptors of immune cells to enhance vaccine efficacy. The strategy is to use this to strengthen vaccine immune responses and boost competitiveness in next-generation vaccine development.
Chief executive Jeong Jae-jun of AriBio LAB said, "This collaboration is a meaningful starting point that combines AriBio LAB's immune-boosting platform technology with Samjin Pharmaceutical's commercialization capabilities," adding, "We will contribute to strengthening domestic vaccine competitiveness and securing vaccine sovereignty through the development of hepatitis B vaccines and next-generation immune-boosting technologies, including the recombinant shingles preventive vaccine 'CVI-VZV-001,' which is currently in phase 2 clinical trials."
Samjin Pharmaceutical President Kim Sang-jin said, "This alliance will serve as a strategic springboard to create tangible synergy in the vaccine field by combining the research and development capabilities of both companies with Samjin Pharmaceutical's sales and marketing know-how," adding, "We will do our best to deliver visible results that contribute to improving public health through continuous research and development and successful commercialization."
AriBio LAB is a biotech corporations that develops next-generation vaccines and immunotherapies. Chief executive Jeong Jae-jun also serves as chief executive of AriBio, which is conducting a global phase 3 clinical trial of the oral Alzheimer's disease drug candidate 'AR1001.' The company is working to expand its pipeline covering both prevention and treatment and to enter the global market, based on core technologies in vaccines and therapies for degenerative brain diseases.